Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions
Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
1. A method for making a pharmaceutical composition for intravenous administration comprising:
providing a solution comprising a tonicity agent, a buffer, and at least one active ingredient selected from the group consisting of nicardipine and/or pharmaceutically acceptable salts thereof;
adjusting the pH of the composition as necessary to achieve a pH within the range of from about 3.6 to 4.7;
further diluting the composition to a final active ingredient concentration from about 0.1 to 0.4 mg/mL; and
filling pharmaceutically acceptable containers with the pre-mixed composition;
the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.
2. The method according to claim 1 , in which the tonicity agent is selected from the group consisting of dextrose and sodium chloride.
3. The method according to claim 1 , further comprising adding at least one cosolvent to the buffered solution.
4. The method according to claim 3 , in which the cosolvent is sorbitol.
5. The method according to claim 2 , wherein providing the solution comprises the steps of providing an initial solution comprising water and at least one buffer at a pH less than about 5.0, and thereafter adding at least one active ingredient to the initial solution.
6. The method according to claim 5 , wherein the initial solution has a pH less than about 3.6.
7. A method for making a pharmaceutical composition for intravenous administration comprising: packaging in a pharmaceutically acceptable container a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:
from about 0.1 to 0.4 mg/mL nicardipine hydrochloride;
a tonicity agent selected from (i) about 4.5% to about 5% dextrose or (ii) about 0.8% to about 0.9% sodium chloride; and
from about 0.01 to about 0.1 mg/mL citric acid;
such that the aqueous solution contained in the pharmaceutically acceptable container does not come into contact with polar polymers;
the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.
8. The method of claim 7 , further comprising at least one pH adjuster selected from the group consisting of hydrochloric acid, sodium hydroxide and a mixture thereof.
9. The method of claim 7 , further comprising from about 1 mg/ml to about 4 mg/ml sorbitol.
10. The method of claim 7 , wherein the container comprises copolyester, polyethylene or polyolefin.
11. A method for making a pharmaceutical composition for intravenous administration comprising: packaging in a pharmaceutically acceptable container a pre-mixed aqueous solution with a pH from about 3.6 to about 4.7 comprising:
from about 0.1 to about 0.2 mg/mL nicardipine hydrochloride;
a tonicity agent selected from (i) about 46 to about 50 mg/mL dextrose or (ii) about 8.3 to about 9 mg/mL sodium chloride; and
from about 0.0192 to about 0.0384 mg/mL citric acid;
such that the aqueous solution contained in the pharmaceutically acceptable container does not come into contact with polar polymers;
the aqueous solution when stored in the container for at least one year at room temperature exhibiting (i) less than a 10% decrease in the concentration of nicardipine hydrochloride and (ii) a total impurity formation of less than about 3%.